3 Results for "

DN 1679

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "DN 1679" in MCE Product Catalog:

Cat. No.: HY-181035
Target:  

PROTACs CDK

Research Areas:  

Cancer

DN1679 is a potent, selective and orally active CRBN-dependent CDK12/13 PROTAC dual degrader. DN1679 shows DC50 of 8.8/9.8 nM (MDA-MB-231), 5.1/6.4 nM (MDA-MB-157) and 17.2/15.8 nM (MDA-MB-468) for CDK12/13. DN1679 can downregulate DNA damage response gene mRNA levels, such as ATM, ATR, BRCA1 and RAD51. DN1679 demonstrates a potent synergistic anti-tumor effect companied with Olaparib (HY-10162). DN1679 can be used for research of triple-negative breast cance .
loading...
    loading...
Cat. No.: HY-W877994
CAS No.: 2505502-00-9
Research Areas:  

Cancer

Thalidomide-6-F-5-pip-CHO is a synthetic E3 ligase ligand-conjugate that can be used for the synthesis of PROTACs, such as DN1679 (HY-181035) .
loading...
    loading...
Cat. No.: HY-181036
Research Areas:  

Cancer

CDK12/13 ligand 3 is a CDK12/13 PROTAC ligand. CDK12/13 ligand 3 can be conjugated with E3 ligase ligand (HY-W093272) and linker to synthesize CDK12/13 PROTAC degrader DN1679 (HY-181035). CDK12/13 ligand 3 can be used for cancer research .
loading...
    loading...